Zydus Lifesciences Gets USFDA Nod For Celecoxib Capsules, Expands Pain Management Portfolio

Zydus Lifesciences Ltd has received final approval from the United States Food and Drug Administration (USFDA) to market Celecoxib Capsules in the US, strengthening its presence in the anti-inflammatory and pain relief segment. The drug is a generic version of Celebrex, widely used for treating arthritis and acute pain.

Key Highlights From The Approval

- Celecoxib is a COX-2 selective nonsteroidal anti-inflammatory drug (NSAID) indicated for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and menstrual pain  
- The approved strengths include 50 mg, 100 mg, 200 mg, and 400 mg capsules  
- Zydus will manufacture the drug at its formulation facility in Ahmedabad SEZ, India  
- The approval adds to Zydus’s growing US generics portfolio, which now includes over 392 final approvals and 460 ANDA filings since FY 2003–04  

Market And Strategic Impact

- Celecoxib had annual US sales of over USD 300 million, according to IQVIA data  
- The approval enhances Zydus’s competitiveness in the chronic pain and inflammation segment, especially amid rising demand for affordable alternatives  
- The company continues to focus on expanding its specialty and generics pipeline in regulated markets  

Outlook

Zydus’s latest approval reflects its consistent regulatory momentum and strategic focus on high-volume therapeutic areas. The launch is expected to contribute meaningfully to its US revenue in FY26.

Sources: Business Standard, Economic Times, Zydus Lifesciences Corporate Filings, USFDA Database, Moneycontrol.